Chien-Chien Jacques Appointed CFO at Rooster Bio
RoosterBio, a Frederick-based leader in stem cell and exosome technologies, has appointed Chien-Chien “CC” Jacques as its new CFO, where she will oversee financial operations as the company advances next-generation stem cell therapies and continues its rapid growth in the regenerative medicine field.
September 20, 2024
| BioBuzz’s mission is simple: to be more connected. Our regionally-focused storytelling, programs, events and experiences connect, amplify and create impact across the life science workforce in growing biohubs. Submit your People On The Move (free and ongoing) to showcase your company’s growth by promoting your new hires and recent promotions. |
RoosterBio, a Frederick, Maryland-based company specializing in stem cell and exosome technologies, has appointed Chien-Chien “CC” Jacques as its new Chief Financial Officer. In her new role, Jacques will oversee RoosterBio’s financial operations as the company continues its mission of advancing next-generation stem cell therapies.
Reflecting on her personal connection to the field, Jacques shared, “Having a child with Lyme disease, I’ve seen firsthand how effective stem cell and exosome therapies are. I’m thrilled to be working at a company that will bring the promise of healing to others suffering with various chronic diseases.”
Tim Kelly, CEO of RoosterBio, expressed his excitement about the new addition, stating, “We are thrilled to have CC join our team as CFO. RoosterBio is growing quickly and we are positioned for continued rapid growth as we expand our offerings to include additional cell types and bioprocess solutions. CC’s experience in high-growth life sciences companies and her hands-on approach to leading the finance function makes her an ideal addition to our leadership team.”
Since its inception, RoosterBio has experienced significant growth in Maryland, transitioning from its early days in the FITCI incubator to becoming a key player in the field of regenerative medicine. The company’s rise is also marked by substantial support from TEDCO’s Maryland Stem Cell Research Fund (MSCRF), which has been instrumental in helping RoosterBio commercialize its MSC-EV technology and solidify its position as an industry innovator.
About Chien-Chien Jacques
Chien-Chien Jacques holds a Master’s Degree in Accounting and Financial Management from the University of Maryland and is a licensed CPA. Most recently, she served as Chief Financial Officer at Nava Health, where she established the company’s first formal accounting department and played a key role in achieving SEC-declared effectiveness during its IPO efforts.
Before that, Jacques was the Vice President of Finance & Accounting at Vigene Biosciences, a gene therapy CDMO. There, she developed and implemented formal accounting practices and managed the financial aspects of the company’s acquisition by Charles River Labs.
With nearly two decades of finance and accounting leadership experience, including over a decade in the biotech and alternative therapies sector, Jacques is dedicated to making advanced medicine more accessible and affordable for all.
About Rooster Bio
RoosterBio accelerates the development of human mesenchymal stem/stromal cells (hMSCs) and exosome/extracellular vesicle (EV) products and processes to support the rapid implementation of scalable advanced therapies. The company offers high-quality hMSCs, bioprocess media, genetic engineering tools, and exosome production solutions, all backed by expert bioprocessing knowledge. This comprehensive approach helps therapeutic developers advance from concept to first-in-human testing and commercial manufacturing with reduced costs and increased productivity. With optimized, scalable processes, Type II Drug Master Files, and cGMP products, RoosterBio has enabled therapeutic programs to navigate their path to clinical translation in under one year.
Driven by a commitment to client success, RoosterBio aims to create a world where safe and effective advanced therapies are rapidly developed and made widely available on a global scale.
Want to know more about Rooster Bio? Join us in Frederick, Maryland, at I-270 Innovations Labs on September 26, 2024. BioBuzz’s CEO, Chris Frew, will sit down with RoosterBio’s CEO, Tim Kelly, to discuss current trends impacting the ATM landscape. They’ll also cover the role of tools providers and CDMOs in the future of drug development, and how RoosterBio continues to enable cutting-edge stem cell therapeutics to reach the market faster and more efficiently right here in Frederick. Register now for free!
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
